A nano-cocktail of an NIR-II emissive fluorophore and organoplatinum(ii) metallacycle for efficient cancer imaging and therapy

Feng Ding, Zhao Chen, Won Young Kim, Amit Sharma, Chonglu Li, Qingying Ouyang, Hua Zhu, Guangfu Yang, Yao Sun, Jong Seung Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The scarcity of efficient imaging technologies for precise cancer treatment greatly drives the development of new nanotheranostic based platforms that enable both diagnostic and therapeutic functions, together in a single formulation. Owing to the complicated physiological microenvironment, nanosystems designed with the possibility of noninvasive real-time monitoring of therapeutic progression in the second near-infrared channel (NIR-II, 1000-1700 nm) could substantially improve the current cancer therapies. Herein, we design a novel NIR-II theranostic nanoprobe, PSY (size ∼110 nm), by incorporating organoplatinum(ii) metallacycles P1 and an organic NIR-II molecular dye, SY1030, into the FDA-approved polymer Pluronic F127. Preliminary in vitro and in vivo studies suggest that PSY is capable of being internalized into glioma U87MG-cells with no significant internalization in non-cancerous tissues. In addition, it shows excellent photostability and minimal background for real-time monitoring the process of therapy in the NIR-II region. Furthermore, in U87MG xenografts and orthotopic breast tumor, PSY demonstrat significantly improved anticancer efficacy compared to a clinically approved Pt(ii)-based anticancer drug, cisplatin. The engineered nano-cocktail PSY offers a simple strategy for delivering the organoplatinum(ii) macrocycle P1 and NIR-II fluorophore SY1030 as a cocktail of diagnostic and therapeutic functions and highlights its promising capacity for future cancer treatment.

Original languageEnglish
Pages (from-to)7023-7028
Number of pages6
JournalChemical Science
Volume10
Issue number29
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

UCON 50-HB-5100
Oncology
Fluorophores
Nanoprobes
Nanosystems
Imaging techniques
Poloxamer
Monitoring
Heterografts
Cisplatin
Tumors
Polymers
Coloring Agents
Tissue
Infrared radiation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

A nano-cocktail of an NIR-II emissive fluorophore and organoplatinum(ii) metallacycle for efficient cancer imaging and therapy. / Ding, Feng; Chen, Zhao; Kim, Won Young; Sharma, Amit; Li, Chonglu; Ouyang, Qingying; Zhu, Hua; Yang, Guangfu; Sun, Yao; Kim, Jong Seung.

In: Chemical Science, Vol. 10, No. 29, 01.01.2019, p. 7023-7028.

Research output: Contribution to journalArticle

Ding, F, Chen, Z, Kim, WY, Sharma, A, Li, C, Ouyang, Q, Zhu, H, Yang, G, Sun, Y & Kim, JS 2019, 'A nano-cocktail of an NIR-II emissive fluorophore and organoplatinum(ii) metallacycle for efficient cancer imaging and therapy', Chemical Science, vol. 10, no. 29, pp. 7023-7028. https://doi.org/10.1039/c9sc02466b
Ding, Feng ; Chen, Zhao ; Kim, Won Young ; Sharma, Amit ; Li, Chonglu ; Ouyang, Qingying ; Zhu, Hua ; Yang, Guangfu ; Sun, Yao ; Kim, Jong Seung. / A nano-cocktail of an NIR-II emissive fluorophore and organoplatinum(ii) metallacycle for efficient cancer imaging and therapy. In: Chemical Science. 2019 ; Vol. 10, No. 29. pp. 7023-7028.
@article{fa983634413748dcb49a7d2c779b85a7,
title = "A nano-cocktail of an NIR-II emissive fluorophore and organoplatinum(ii) metallacycle for efficient cancer imaging and therapy",
abstract = "The scarcity of efficient imaging technologies for precise cancer treatment greatly drives the development of new nanotheranostic based platforms that enable both diagnostic and therapeutic functions, together in a single formulation. Owing to the complicated physiological microenvironment, nanosystems designed with the possibility of noninvasive real-time monitoring of therapeutic progression in the second near-infrared channel (NIR-II, 1000-1700 nm) could substantially improve the current cancer therapies. Herein, we design a novel NIR-II theranostic nanoprobe, PSY (size ∼110 nm), by incorporating organoplatinum(ii) metallacycles P1 and an organic NIR-II molecular dye, SY1030, into the FDA-approved polymer Pluronic F127. Preliminary in vitro and in vivo studies suggest that PSY is capable of being internalized into glioma U87MG-cells with no significant internalization in non-cancerous tissues. In addition, it shows excellent photostability and minimal background for real-time monitoring the process of therapy in the NIR-II region. Furthermore, in U87MG xenografts and orthotopic breast tumor, PSY demonstrat significantly improved anticancer efficacy compared to a clinically approved Pt(ii)-based anticancer drug, cisplatin. The engineered nano-cocktail PSY offers a simple strategy for delivering the organoplatinum(ii) macrocycle P1 and NIR-II fluorophore SY1030 as a cocktail of diagnostic and therapeutic functions and highlights its promising capacity for future cancer treatment.",
author = "Feng Ding and Zhao Chen and Kim, {Won Young} and Amit Sharma and Chonglu Li and Qingying Ouyang and Hua Zhu and Guangfu Yang and Yao Sun and Kim, {Jong Seung}",
year = "2019",
month = "1",
day = "1",
doi = "10.1039/c9sc02466b",
language = "English",
volume = "10",
pages = "7023--7028",
journal = "Chemical Science",
issn = "2041-6520",
publisher = "Royal Society of Chemistry",
number = "29",

}

TY - JOUR

T1 - A nano-cocktail of an NIR-II emissive fluorophore and organoplatinum(ii) metallacycle for efficient cancer imaging and therapy

AU - Ding, Feng

AU - Chen, Zhao

AU - Kim, Won Young

AU - Sharma, Amit

AU - Li, Chonglu

AU - Ouyang, Qingying

AU - Zhu, Hua

AU - Yang, Guangfu

AU - Sun, Yao

AU - Kim, Jong Seung

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The scarcity of efficient imaging technologies for precise cancer treatment greatly drives the development of new nanotheranostic based platforms that enable both diagnostic and therapeutic functions, together in a single formulation. Owing to the complicated physiological microenvironment, nanosystems designed with the possibility of noninvasive real-time monitoring of therapeutic progression in the second near-infrared channel (NIR-II, 1000-1700 nm) could substantially improve the current cancer therapies. Herein, we design a novel NIR-II theranostic nanoprobe, PSY (size ∼110 nm), by incorporating organoplatinum(ii) metallacycles P1 and an organic NIR-II molecular dye, SY1030, into the FDA-approved polymer Pluronic F127. Preliminary in vitro and in vivo studies suggest that PSY is capable of being internalized into glioma U87MG-cells with no significant internalization in non-cancerous tissues. In addition, it shows excellent photostability and minimal background for real-time monitoring the process of therapy in the NIR-II region. Furthermore, in U87MG xenografts and orthotopic breast tumor, PSY demonstrat significantly improved anticancer efficacy compared to a clinically approved Pt(ii)-based anticancer drug, cisplatin. The engineered nano-cocktail PSY offers a simple strategy for delivering the organoplatinum(ii) macrocycle P1 and NIR-II fluorophore SY1030 as a cocktail of diagnostic and therapeutic functions and highlights its promising capacity for future cancer treatment.

AB - The scarcity of efficient imaging technologies for precise cancer treatment greatly drives the development of new nanotheranostic based platforms that enable both diagnostic and therapeutic functions, together in a single formulation. Owing to the complicated physiological microenvironment, nanosystems designed with the possibility of noninvasive real-time monitoring of therapeutic progression in the second near-infrared channel (NIR-II, 1000-1700 nm) could substantially improve the current cancer therapies. Herein, we design a novel NIR-II theranostic nanoprobe, PSY (size ∼110 nm), by incorporating organoplatinum(ii) metallacycles P1 and an organic NIR-II molecular dye, SY1030, into the FDA-approved polymer Pluronic F127. Preliminary in vitro and in vivo studies suggest that PSY is capable of being internalized into glioma U87MG-cells with no significant internalization in non-cancerous tissues. In addition, it shows excellent photostability and minimal background for real-time monitoring the process of therapy in the NIR-II region. Furthermore, in U87MG xenografts and orthotopic breast tumor, PSY demonstrat significantly improved anticancer efficacy compared to a clinically approved Pt(ii)-based anticancer drug, cisplatin. The engineered nano-cocktail PSY offers a simple strategy for delivering the organoplatinum(ii) macrocycle P1 and NIR-II fluorophore SY1030 as a cocktail of diagnostic and therapeutic functions and highlights its promising capacity for future cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=85069786974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069786974&partnerID=8YFLogxK

U2 - 10.1039/c9sc02466b

DO - 10.1039/c9sc02466b

M3 - Article

VL - 10

SP - 7023

EP - 7028

JO - Chemical Science

JF - Chemical Science

SN - 2041-6520

IS - 29

ER -